Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies CAMBRIDGE, Mass. and CARLSBAD, Calif., June 24, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.

Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University CAMBRIDGE, Mass. and CARLSBAD, Calif., May 6, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.

Companies Announce Significant microRNA Therapeutics Collaboration

Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer CAMBRIDGE, Mass. and CARLSBAD, Calif., February 11, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.

Findings Published in Nature Show Potential of Targeting MicroRNAs to Treat Diseases

Role of MicroRNA-122 in Hepatitis C Infection Published in Science

Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications Intellectual Property From Max Planck Society Strengthens Companies’ Leadership Positions In RNA-Based Drug Discovery and Development CAMBRIDGE, Mass., and CARLSBAD, Calif., Oct.